查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1768750

下一代定序（NGS）資料分析的全球市場

Next Generation Sequencing (NGS) Data Analysis
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 437 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球次世代定序資料分析市場規模將達 23 億美元

全球新一代定序 (NGS) 數據分析市場規模預計在 2024 年達到 10 億美元，預計到 2030 年將達到 23 億美元，2024 年至 2030 年的複合年成長率為 13.9%。服務是本報告分析的細分市場之一，預計其複合年成長率為 14.7%，到分析期結束時規模將達到 14 億美元。 NGS 商業軟體細分市場在分析期間的複合年成長率預計為 12.7%。

美國市場規模估計為 3.653 億美元，中國市場預計複合年成長率為 15.2%

美國次世代定序資料分析市場規模預計在2024年達到3.653億美元。預計到2030年，作為世界第二大經濟體的中國市場規模將達到2.292億美元，在2024-2030年的分析期內，複合年成長率為15.2%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為12.9%和13.0%。在歐洲，預計德國市場的複合年成長率約為13.6%。

全球下一代定序資料分析市場—主要趨勢與促進因素摘要

什麼是次世代定序資料分析？為什麼它具有革命性？

下一代定序資料分析是指解讀下一代定序技術所產生的海量資料的過程。 NGS 可以比以往的桑格定序更快、更經濟地對 DNA 和 RNA 進行定序，產生大量資料。分析這些數據需要生物資訊工具和軟體來處理數據、比對、組裝和註釋，將原始序列數據轉化為可理解的遺傳資訊。這些資訊對於基因組學、腫瘤學、藥物基因組學和複雜疾病研究等廣泛的科學應用至關重要。 NGS 能夠提供高通量、可擴展且超快速的定序，使其成為現代遺傳學研究的基石，徹底改變了我們對生物系統的理解。

技術進步如何影響下一代定序資料分析？

新一代定序資料分析領域受益於生物資訊學、雲端運算和人工智慧的不斷進步。生物資訊學已發展到能夠透過複雜的演算法和軟體來管理數據的複雜性和規模，從而實現更快、更準確的分析。雲端處理透過實現遠端儲存和處理大量資料集，徹底改變了資料分析，為全球研究人員提供了可擴展性和可存取性。此外，人工智慧和機器學習已開始透過自動化模式識別在提高遺傳數據分析效率方面發揮關鍵作用，這對於理解基因突變和功能至關重要。這些技術正在增強我們預測疾病感受性和藥物反應的能力，為個人化醫療鋪平道路。

下一代定序資料分析面臨的主要挑戰和機會是什麼？

儘管新一代定序資料分析取得了長足進步，但仍面臨諸多挑戰。其中最大的挑戰之一是如何管理大量數據，這需要強大的運算能力和強大的數據管理系統才能有效處理。此外，數據解讀的複雜性需要經驗豐富的生物資訊學家和遺傳學家來確保分析的準確性。此外，將新一代定序資料與其他類型的生物資料整合，以全面洞察複雜的基因結構也面臨挑戰。然而，這些挑戰正在推動計算生物學的創新，從而開發出更複雜的分析工具和方法，不斷提高新一代定序資料分析的速度、準確性和成本效益。

哪些因素推動了下一代定序資料分析市場的成長？

下一代定序資料分析市場的成長受到反映技術、經濟和社會變化的多種因素的驅動。定序技術的進步提高了基因定序的通量並降低了成本，擴大了NGS在醫學研究、臨床診斷和個人化醫療等各種應用領域的應用。巨量資料分析的整合和增強的運算能力使得數據分析更加先進和快速，滿足了對快速獲得結果日益成長的需求。在經濟方面，全球生物技術和製藥行業的擴張推動了對基因組學和NGS的投資，進一步推動了市場成長。在社會方面，公眾和醫療保健提供者對基因組醫學的認知和接受度越來越高，這得到了政府推動精準醫療的措施的支持。

部分

組件（服務、NGS 商業軟體）、工作流程（三級數據分析、一級數據分析、二級數據分析）、模式（內部、外包）、最終用戶（學術研究、臨床研究、醫院和診所、製藥和生物技術公司、其他最終用戶）

受訪公司範例

  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • AB Sciex LLC
  • Asuragen, Inc.
  • Adaptive Biotechnologies Corporation
  • BGI-Shenzhen
  • Beijing Novogene Bioinformatics Technology Co., Ltd.
  • ABL（Advanced Biological Laboratories）SA
  • Admera Health
  • Arima Genomics
  • 1010Genome
  • Basepair
  • BGI Genomics

人工智慧整合

全球產業分析師正在利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global 特定產業SLM 的典型規範，而是建立了一個來自全球專家的精選內容庫，其中包括視訊錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口狀況（成品和原始OEM）預測其競爭態勢的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括銷貨成本成本 (COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 比賽

簡介目錄
Product Code: MCP22378

Global Next Generation Sequencing (NGS) Data Analysis Market to Reach US$2.3 Billion by 2030

The global market for Next Generation Sequencing (NGS) Data Analysis estimated at US$1.0 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 13.9% over the analysis period 2024-2030. Services, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Ngs Commercial Software segment is estimated at 12.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$365.3 Million While China is Forecast to Grow at 15.2% CAGR

The Next Generation Sequencing (NGS) Data Analysis market in the U.S. is estimated at US$365.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$229.2 Million by the year 2030 trailing a CAGR of 15.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 13.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.6% CAGR.

Global Next Generation Sequencing (NGS) Data Analysis Market - Key Trends & Drivers Summarized

What Is Next Generation Sequencing (NGS) Data Analysis, and Why Is It Revolutionary?

Next Generation Sequencing (NGS) data analysis refers to the process of interpreting the vast amounts of data produced by next generation sequencing technologies. NGS allows for the sequencing of DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing, and it generates massive volumes of data. The analysis of these data involves bioinformatics tools and software that handle data processing, alignment, assembly, and annotation to translate raw sequencing data into understandable genetic information. This information is crucial for a broad range of scientific applications, including genomics, oncology, pharmacogenomics, and complex disease studies. The ability of NGS to provide high-throughput, scalable, and ultra-fast sequencing makes it a cornerstone in modern genetic research, transforming our understanding of biological systems.

How Are Technological Advancements Shaping NGS Data Analysis?

The field of NGS data analysis has greatly benefited from continual advancements in bioinformatics, cloud computing, and artificial intelligence. Bioinformatics has evolved to manage the complexity and size of data through sophisticated algorithms and software that can deliver faster and more accurate analysis. Cloud computing has revolutionized data analysis by enabling the storage and processing of enormous datasets remotely, providing scalability and accessibility to researchers around the world. Furthermore, AI and machine learning have begun to play pivotal roles in improving the efficiency of genetic data analysis by automating pattern recognition, which is crucial for understanding genetic variations and functions. These technologies enhance the ability to predict disease susceptibility and drug responses, paving the way for personalized medicine.

What Are the Major Challenges and Opportunities in NGS Data Analysis?

Despite its advancements, NGS data analysis faces significant challenges that also present opportunities for growth and improvement. One of the primary hurdles is the management of the sheer volume of data generated, which requires substantial computational power and robust data management systems to handle effectively. Additionally, the complexity of data interpretation demands highly skilled bioinformaticians and geneticists to ensure accurate analyses. There is also the challenge of integrating NGS data with other types of biological data to provide comprehensive insights into complex genetic structures. However, these challenges drive innovation in computational biology, leading to the development of more sophisticated analysis tools and methodologies that continually improve the speed, accuracy, and cost-effectiveness of NGS data analysis.

What Factors Are Propelling the Growth of the NGS Data Analysis Market?

Growth in the NGS data analysis market is driven by several factors that reflect technological, economic, and social shifts. Technological advances in sequencing technologies continue to increase the throughput and reduce the cost of genetic sequencing, expanding the accessibility of NGS for various applications in medical research, clinical diagnostics, and personalized medicine. The integration of big data analytics and enhanced computational power allows for more sophisticated and quicker data analysis, catering to the growing demand for rapid results. Economically, the expansion of biotechnology and pharmaceutical sectors worldwide fuels investment in genomics and NGS, further promoting market growth. Socially, there is a rising awareness and acceptance of genomic medicine among the public and healthcare providers, which is supported by government initiatives promoting precision medicine.

SCOPE OF STUDY:

The report analyzes the Next Generation Sequencing (NGS) Data Analysis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Services, NGS Commercial Software); Workflow (Tertiary Data Analysis, Primary Data Analysis, Secondary Data Analysis); Mode (In-House, Outsourced); End-Use (Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 111 Featured) -

  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • AB Sciex LLC
  • Asuragen, Inc.
  • Adaptive Biotechnologies Corporation
  • BGI-Shenzhen
  • Beijing Novogene Bioinformatics Technology Co., Ltd.
  • ABL (Advanced Biological Laboratories) SA
  • Admera Health
  • Arima Genomics
  • 1010Genome
  • Basepair
  • BGI Genomics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Next Generation Sequencing (NGS) Data Analysis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • NGS Data Analysis: Unraveling Critical Clues to Solve Scientific Problems
    • NGS Data Analysis: Insights into File Formats & Downstream Analysis
    • File Formats for NGS Raw Data
    • NGS Data: Downstream Analysis
    • Global Market Overview and Prospects
    • Next-Generation Sequencing (NGS) Data Analysis Market Witnesses Burgeoning Growth
    • Key Market Drivers and Inhibitors
    • Market Analysis
    • US and Europe Lead, Asia-Pacific to Witness Growth
    • Analysis by Product
    • Analysis by Workflow
    • Analysis by Mode
    • Analysis by Read Length
    • Analysis by End-Use
    • Competitive Landscape
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Next Generation Sequencing Market Drives the Demand for NGS Data Analysis
    • Increasing R&D Activities in NGS
    • Rising Use of NGS in Drug Discovery Drives Growth of NGS Data Analysis
    • Rising Application of Whole Genome Sequencing Drives Demand for Faster Secondary Analysis Tools
    • Technological Advancements in Sequencing Techniques and Data Integration
    • Research Initiatives for the Development of NGS-based In-vitro Diagnostics
    • The Need for Large-scale NGS Data Analysis Pushes for Cloud-enabled Bioinformatics Services
    • NGS Data Analysis Using Big Data Gains Ground
    • Improving Regulatory & Reimbursement Scenario for NGS-based Diagnostic Tests
    • Increase in Genome Mapping Programs
    • Declining Costs of Genome Sequencing Drive Market Growth
    • Growth of Long-Read Sequencing to Propel the Market for NGS Data Analysis
    • Aging Demographics Present Opportunities
    • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Growing Prevalence of Chronic Diseases to Boost the Market Prospects
    • Rising Diabetes Prevalence: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Market Challenges
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ngs Commercial Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Ngs Commercial Software by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Tertiary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Tertiary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Primary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Primary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Secondary Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Secondary Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for In-House by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for In-House by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Outsourced by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Outsourced by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World 6-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 22: World 6-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pharma & Biotech Entities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World 6-Year Perspective for Pharma & Biotech Entities by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 26: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 27: World Next Generation Sequencing (NGS) Data Analysis Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • CANADA
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • JAPAN
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • CHINA
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 52: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • EUROPE
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • FRANCE
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 70: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • GERMANY
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Italy 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • UNITED KINGDOM
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 94: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: UK 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 96: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: UK 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Next Generation Sequencing (NGS) Data Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 118: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Component - Services and Ngs Commercial Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of World 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Component - Percentage Breakdown of Value Revenues for Services and Ngs Commercial Software for the Years 2025 & 2030
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Workflow - Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of World 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Workflow - Percentage Breakdown of Value Revenues for Tertiary Data Analysis, Primary Data Analysis and Secondary Data Analysis for the Years 2025 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by Mode - In-House and Outsourced - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown of Value Revenues for In-House and Outsourced for the Years 2025 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Next Generation Sequencing (NGS) Data Analysis by End-Use - Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of World 6-Year Perspective for Next Generation Sequencing (NGS) Data Analysis by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses, Academic Research and Clinical Research for the Years 2025 & 2030

IV. COMPETITION